増殖性硝子体網膜症（PVR）治療の世界市場 2020年

• 英文タイトル：Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

• レポートコード：GIR201107550 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール • 産業分類：医薬品・医療

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本書では、増殖性硝子体網膜症（PVR）治療の世界市場を調査対象にし、増殖性硝子体網膜症（PVR）治療の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（PRM-167、XOMA-089、その他）、用途別分析（病院、クリニック、ASC、その他）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：Novartis AG、Promedior Inc、RXi Pharmaceuticals Corp ・メーカー別販売量、売上、市場シェア ・増殖性硝子体網膜症（PVR）治療の地域別市場分析 ・増殖性硝子体網膜症（PVR）治療の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・増殖性硝子体網膜症（PVR）治療のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・増殖性硝子体網膜症（PVR）治療のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・増殖性硝子体網膜症（PVR）治療の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・増殖性硝子体網膜症（PVR）治療の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・増殖性硝子体網膜症（PVR）治療の種類別市場規模2015-2020：PRM-167、XOMA-089、その他 ・増殖性硝子体網膜症（PVR）治療の用途別市場規模2015-2020：病院、クリニック、ASC、その他 ・増殖性硝子体網膜症（PVR）治療の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論

Market Overview
The global Proliferative Vitreoretinopathy (PVR) Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Proliferative Vitreoretinopathy (PVR) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Proliferative Vitreoretinopathy (PVR) Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Proliferative Vitreoretinopathy (PVR) Therapeutics market has been segmented into
PRM-167
XOMA-089
Others

By Application, Proliferative Vitreoretinopathy (PVR) Therapeutics has been segmented into:
Hospital
Clinic
ASCs
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Proliferative Vitreoretinopathy (PVR) Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Proliferative Vitreoretinopathy (PVR) Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Proliferative Vitreoretinopathy (PVR) Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Proliferative Vitreoretinopathy (PVR) Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Competitive Landscape and Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share Analysis
Proliferative Vitreoretinopathy (PVR) Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Proliferative Vitreoretinopathy (PVR) Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Proliferative Vitreoretinopathy (PVR) Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Proliferative Vitreoretinopathy (PVR) Therapeutics are:
Novartis AG
Promedior Inc
RXi Pharmaceuticals Corp

Among other players domestic and global, Proliferative Vitreoretinopathy (PVR) Therapeutics market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Proliferative Vitreoretinopathy (PVR) Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics, with price, sales, revenue and global market share of Proliferative Vitreoretinopathy (PVR) Therapeutics in 2018 and 2019.
Chapter 3, the Proliferative Vitreoretinopathy (PVR) Therapeutics competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Proliferative Vitreoretinopathy (PVR) Therapeutics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Proliferative Vitreoretinopathy (PVR) Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Proliferative Vitreoretinopathy (PVR) Therapeutics sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

Table of Contents

1 Market Overview
1.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 PRM-167
1.2.3 XOMA-089
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 ASCs
1.3.5 Others
1.4 Overview of Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market
1.4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Novartis AG
2.1.1 Novartis AG Details
2.1.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Novartis AG SWOT Analysis
2.1.4 Novartis AG Product and Services
2.1.5 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Promedior Inc
2.2.1 Promedior Inc Details
2.2.2 Promedior Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Promedior Inc SWOT Analysis
2.2.4 Promedior Inc Product and Services
2.2.5 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 RXi Pharmaceuticals Corp
2.3.1 RXi Pharmaceuticals Corp Details
2.3.2 RXi Pharmaceuticals Corp Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 RXi Pharmaceuticals Corp SWOT Analysis
2.3.4 RXi Pharmaceuticals Corp Product and Services
2.3.5 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturer Market Share in 2019
3.3.2 Top 6 Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Market Share by Regions
4.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Market Share by Regions (2015-2020)
4.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Market Share by Regions (2015-2020)
4.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
4.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
4.5 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Market Share by Country
5.1.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Market Share by Country (2015-2020)
5.1.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Market Share by Country (2015-2020)
5.2 United States Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
5.3 Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
5.4 Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Market Share by Country
6.1.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Market Share by Country (2015-2020)
6.1.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Market Share by Country (2015-2020)
6.2 Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
6.3 UK Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
6.4 France Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
6.5 Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
6.6 Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Market Share by Regions (2015-2020)
7.2 China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
7.3 Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
7.4 Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
7.5 India Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
7.7 Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Market Share by Country
8.1.1 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Market Share by Country (2015-2020)
8.1.2 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Market Share by Country (2015-2020)
8.2 Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
8.3 Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
9.3 Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
9.4 Egypt Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
9.5 South Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Market Share by Type (2015-2020)
10.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Market Share by Type (2015-2020)
10.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2015-2020)
11 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Segment by Application
11.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2015-2020)
11.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2015-2020)
11.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2015-2020)
12 Market Forecast
12.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Growth Rate (2021-2025)
12.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast by Regions (2021-2025)
12.2.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast (2021-2025)
12.2.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast (2021-2025)
12.2.3 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast (2021-2025)
12.2.4 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast (2021-2025)
12.2.5 Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast (2021-2025)
12.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast by Type (2021-2025)
12.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Type (2021-2025)
12.3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share Forecast by Type (2021-2025)
12.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast by Application (2021-2025)
12.4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Application (2021-2025)
12.4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US

List of Tables

Table 1. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Proliferative Vitreoretinopathy (PVR) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 8. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Major Business
Table 9. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Total Revenue (USD Million) (2018-2019)
Table 10. Novartis AG SWOT Analysis
Table 11. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product and Services
Table 12. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Promedior Inc Basic Information, Manufacturing Base and Competitors
Table 14. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Major Business
Table 15. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Total Revenue (USD Million) (2018-2019)
Table 16. Promedior Inc SWOT Analysis
Table 17. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product and Services
Table 18. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. RXi Pharmaceuticals Corp Basic Information, Manufacturing Base and Competitors
Table 20. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Major Business
Table 21. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Total Revenue (USD Million) (2018-2019)
Table 22. RXi Pharmaceuticals Corp SWOT Analysis
Table 23. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product and Services
Table 24. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturer (2018-2019) (K Pcs)
Table 26. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturer (2018-2019) (USD Million)
Table 27. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Regions (2015-2020) (K Pcs)
Table 28. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Regions (2015-2020)
Table 29. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Regions (2015-2020) (USD Million)
Table 30. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Countries (2015-2020) (K Pcs)
Table 31. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Countries (2015-2020)
Table 32. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Countries (2015-2020) (USD Million)
Table 33. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 34. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Countries (2015-2020) (K Pcs)
Table 35. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Countries (2015-2020)
Table 36. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Countries (2015-2020) (USD Million)
Table 37. Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Regions (2015-2020) (K Pcs)
Table 38. Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Regions (2015-2020)
Table 39. Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Regions (2015-2020) (USD Million)
Table 40. South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Countries (2015-2020) (K Pcs)
Table 41. South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Countries (2015-2020)
Table 42. South America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Countries (2015-2020) (USD Million)
Table 43. South America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 44. Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Countries (2015-2020) (K Pcs)
Table 45. Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Countries (2015-2020)
Table 46. Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Countries (2015-2020) (USD Million)
Table 47. Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 48. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 49. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Type (2015-2020)
Table 50. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2015-2020) (USD Million)
Table 51. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Type (2015-2020)
Table 52. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 53. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Application (2015-2020)
Table 54. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Regions (2021-2025) (K Pcs)
Table 55. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share Forecast by Regions (2021-2025)
Table 56. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Type (2021-2025) (K Pcs)
Table 57. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share Forecast by Type (2021-2025)
Table 58. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Application (2021-2025)
Table 59. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share Forecast by Application (2021-2025)
Table 60. Direct Channel Pros & Cons
Table 61. Indirect Channel Pros & Cons
Table 62. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Proliferative Vitreoretinopathy (PVR) Therapeutics Picture
Figure 2. Global Sales Market Share of Proliferative Vitreoretinopathy (PVR) Therapeutics by Type in 2019
Figure 3. PRM-167 Picture
Figure 4. XOMA-089 Picture
Figure 5. Others Picture
Figure 6. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application in 2018
Figure 7. Hospital Picture
Figure 8. Clinic Picture
Figure 9. ASCs Picture
Figure 10. Others Picture
Figure 11. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Status and Outlook (2015-2025) (USD Million)
Figure 12. United States Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 16. France Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 17. UK Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 20. China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 23. India Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Southeast Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 26. Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Egypt Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 29. South Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Manufacturer in 2019
Figure 32. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Manufacturer in 2019
Figure 33. Top 3 Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturer (Revenue) Market Share in 2019
Figure 34. Top 6 Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturer (Revenue) Market Share in 2019
Figure 35. Key Manufacturer Market Share Trend
Figure 36. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 37. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Growth Rate (2015-2020) (USD Million)
Figure 38. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 39. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Regions in 2018
Figure 40. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
Figure 41. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
Figure 43. South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
Figure 44. Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020)
Figure 45. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Growth Rate (2015-2020) (USD Million)
Figure 46. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Countries (2015-2020)
Figure 47. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Countries in 2018
Figure 48. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 49. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Countries in 2018
Figure 50. United States Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 51. Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 52. Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 53. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Growth Rate (2015-2020) (USD Million)
Figure 54. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 55. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Countries in 2019
Figure 56. Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 57. UK Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 58. France Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Growth Rate (2015-2020) (USD Million)
Figure 62. Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Regions 2019
Figure 63. Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Regions 2019
Figure 64. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 66. Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. India Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. Southeast Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. South America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Growth Rate (2015-2020) (USD Million)
Figure 70. South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Countries in 2019
Figure 71. South America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Countries in 2019
Figure 72. Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 73. Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 74. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Growth Rate (2015-2020) (USD Million)
Figure 75. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Countries in 2019
Figure 76. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 77. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Countries in 2019
Figure 78. Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 79. Egypt Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 80. Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. South Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Growth Rate (2021-2025) (K Pcs)
Figure 83. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue and Growth Rate (2021-2025) (USD Million)
Figure 84. North America Sales Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast (2021-2025) (K Pcs)
Figure 85. Europe Sales Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast (2021-2025) (K Pcs)
Figure 86. Asia-Pacific Sales Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast (2021-2025) (K Pcs)
Figure 87. South America Sales Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast (2021-2025) (K Pcs)
Figure 88. Middle East & Africa Sales Proliferative Vitreoretinopathy (PVR) Therapeutics Market Forecast (2021-2025) (K Pcs)
Figure 89. Sales Channel: Direct Channel vs Indirect Channel

---